Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 5 – 1 PHG Matrix Metrics: DXCM 7 – 3 PHG

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PHG trades in a Markup technical trend (SURGE options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs PHG
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
PHG NYSE
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap $28.6B
TTM Revenue $17.8B
Forward P/E 14.0x
Beta / 30D Vol 0.71β · 38% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 15.0 Fund 39.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $29.08 · SMA50: $26.59

6-Pillar Scorecard Institutional Category Breakdown (DXCM 5 – 1 PHG)

Columns: Metric · DXCM · PHG
1. Valuation Multiples PHG
Forward P/E 25.3x 14.0x
Trailing P/E 31.6x 25.4x
PEG Ratio 1.30x 0.90x
EV / Revenue 5.9x 1.9x
2. Growth & Scale DXCM
Revenue Growth (YoY) +11.2% +2.1%
Earnings Growth (YoY) +2.6% -85.4%
TTM Revenue (USD) $5.10B $17.8B
Market Cap $29.9B $28.6B
3. Profitability & Quality DXCM
Gross Margin 63.4% 46.4%
Operating Margin 24.0% 8.8%
Net Profit Margin 19.4% 5.4%
Return on Equity (ROE) 37.7% 8.6%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $1.82B
Cash Flow Margin 33.9% 10.3%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $5.39B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 63.0% (15th %ile) 111.5% (51st %ile)
Put/Call OI Skew 0.48x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DXCM
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 37.6% of Rev ($6.68B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (7) vs PHG (3)
Institutional Metric DXCM PHG Criterion Row Edge
Market Capitalization
Scale
$29.9B $28.6B Larger Scale DXCM
Trailing P/E Ratio
Valuation
31.6x 25.4x Lower Multiple PHG
Forward P/E Ratio
Valuation
25.3x 14.0x Lower Multiple PHG
Revenue Growth (YoY)
Growth
+11.2% +2.1% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 8.8% Higher Margin DXCM
Net Profit Margin
Profitability
19.4% 5.4% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 8.6% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 51% ($24–$33) Stronger Trend DXCM
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.71β · 38% Vol Lower Realized Risk PHG
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $17.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 0.90x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $1.82B ($5.39B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHG +5.0 pp
DXCM: +1.28% · PHG: +6.28%
3M Horizon PHG +16.85 pp
DXCM: -12.89% · PHG: +3.96%
6M Horizon DXCM +3.85 pp
DXCM: +10.01% · PHG: +6.16%
1Y Horizon DXCM +27.07 pp
DXCM: +32.8% · PHG: +5.73%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue PHG Revenue DXCM Op. Margin PHG Op. Margin Margin Leader
Q3 '25 $4.84B $17.2B 20.1% 7.7% DXCM
Q4 '25 $5.04B $20.4B 25.6% 11.1% DXCM
Q1 '26 $4.77B $15.6B 21.4% 6.2% DXCM
Q2 '26 $5.23B $17.4B 24.3% 14.0% DXCM
Q3 '26 $5.38B $17.6B 24.3% 3.8% DXCM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
12d in phase · OBV DISTRIBUTION
Current IV 111.5%
IV Percentile 51st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,161)

Compare $8,161 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 39.6% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $85 / $75 Bear Put Spread

Buy 1x $85P · Sell 1x $75P · 31d

Net Entry $380 Debit
T+5d @ -5% Drop +$186 (+49%)
Max Risk / Buffer $380 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($6.68B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs PHG Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Koninklijke Philips N.V. (PHG) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile PHG trades in a Markup technical trend (SURGE options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), DXCM cumulative revenue shifted +11.2% while PHG shifted +2.1%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($6.68B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.